The failure of MEK inhibitors against KRAS mutant lung cancers and the low percentage of sustained durable responses with anti-PD-1/PD-L1 immune checkpoint blockade therapies emphasize the need to understand drug resistance mechanisms to improve patient survival. The gene discussed is KRAS; the disease is lung cancer.